Trillium Therapeutics Inc. (NASDAQ: TRIL) today announced that it has entered into subscription agreements for the sale of 1,950,000 common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE